Vol. 11, Issue 1 (2025)

The advent of 3D bioprinting has emerged as a transformative technology in orthopedic medicine, bridging the gap between regenerative medicine and personalized healthcare. By utilizing bioinks—combinations of living cells and biocompatible materials—this technology allows the fabrication of anatomically precise scaffolds and implants that closely mimic native bone, cartilage, and musculoskeletal structures. Recent advancements have demonstrated remarkable clinical successes. For instance, bioprinted bone scaffolds infused with osteogenic factors have shown an 80% increase in bone regeneration rates in preclinical models, while cartilage repair using bioprinted constructs has led to functional recovery in over 70% of patients within one year of treatment.

The global market for 3D bioprinting in orthopedics is projected to grow at a compound annual growth rate (CAGR) of 18.7%, expected to reach $4.4 billion by 2028, reflecting the increasing demand for precision medicine and customized implants. Clinical applications span from treating critical-sized bone defects and osteochondral injuries to personalized joint reconstructions and spinal implants. Moreover, bioprinted scaffolds have reduced revision surgery rates by 25%, highlighting their long-term benefits.

Despite these advancements, challenges such as vascularization, high production costs, and regulatory hurdles remain significant barriers to widespread adoption. Nevertheless, emerging technologies like AI-driven modeling and 4D bioprinting hold promise for overcoming these limitations. This review explores the materials, methodologies, clinical applications, and future directions of 3D bioprinting in orthopedics, emphasizing its potential to redefine the standard of care and improve patient outcomes.